UNSPSC 51285902: Cilastatin

This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 141A6AMN38. European Medicines Agency schedules Cilastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06264MIG. Cilastatin generally arises in the molecular formula C16H26N2O5S.

The term CILASTATIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 38, no. 6, 1984, list 24.) CILASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C(N/C(=C\CCC)C(=O)O)C1C(C1)(C)C.

UNSPSC 51285902 Cilastatin, a Commodity code, covers pharmaceutical procurement by state and local health agencies, though recent activity in the code shows limited direct alignment with the cilastatin product itself. State and local governments buying under this code are primarily health departments and county public health systems acquiring injectable antibiotics and related pharmaceutical products for clinical and emergency use. The Illinois Department of Public Health and Seminole County, Florida represent the issuing-body mix typical for pharmaceutical commodity codes — state health departments and county health systems acquiring drugs through competitive bidding, often via cooperative purchasing vehicles such as MMCAP. Procurement tends to flow through piggyback contracts and group purchasing agreements that leverage existing state or multi-state frameworks to streamline vendor competition and pricing.

Recent activity in this code spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 (Solicitation 26482DPHPREPDB53392) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets over a three-year term via an Invitation for Bid process. Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries; the bid deadline was July 26, 2023. Both procurements include compliance requirements such as drug-free workplace certification and E-Verify, and both are sourced through established competitive bidding rather than sole-source arrangements.